Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology

Tissue Repair

LL-37

Cathelicidin; hCAP-18 C-terminus

Cathelicidin antimicrobial peptide; host-defense

This LL-37 entry draws on 24 cited sources published 2015 to 2026. The evidence available is graded Preclinical + Animal Studies on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
Cathelicidin antimicrobial peptide; host-defense
Drug class
Tissue Repair
Structure
37-aa peptide LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Route
SC / Topical
Half-life
Short (minutes)
Evidence tier
Preclinical + Animal Studies
Availability
Research
Research depth
309 indexed citations (PubMed 192 · CT 50 · EPMC 67) →

Mechanism of action

Cationic amphipathic α-helix disrupts microbial membranes; modulates host immune response

Reported areas of research

Broad-spectrum antimicrobial; wound healing; biofilm disruption; immune modulation

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

100-500 mcg SC daily (research)

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Pro-inflammatory at high doses (rosacea link); cytotoxicity at high concentrations

Frequently asked questions

What dosing is reported for LL-37 in research literature?

Published peptide research reports the following dosing approach for LL-37: 100-500 mcg SC daily (research). This is a research reference, not a clinical recommendation.

How is LL-37 administered in research?

LL-37 is administered via the following routes in published studies: SC / Topical.

What is the reported half-life of LL-37?

No measured half-life for LL-37 is reported in the literature catalogued here. The catalog describes it as: Short (minutes).

Is LL-37 FDA-approved?

No. LL-37 is not an FDA-approved drug. LL-37 was nominated for FDA's bulk drug substance lists, flagged by FDA for possible safety risks, and the nomination was then withdrawn by the party that filed it, which leaves it with no route to lawful compounding rather than with a clean record. PeptideHelper.org catalog status: Research.

Sources: FDA: bulk drug substances that may present significant safety risks.

What level of evidence supports LL-37?

The current evidence base for LL-37 is best characterised as: Preclinical + Animal Studies. See the methodology page for the full evidence-tier rubric.

What side effects are reported for LL-37?

Known concerns reported in the literature for LL-37 include: Pro-inflammatory at high doses (rosacea link); cytotoxicity at high concentrations. Always consult a qualified clinician before any human use.

Is there anyone who should not use LL-37?

No formal contraindications are established for LL-37, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Pro-inflammatory at high doses (rosacea link); cytotoxicity at high concentrations. Always consult a qualified clinician before any human use.

How does LL-37 work?

The mechanism of action reported for LL-37 in the literature: Cationic amphipathic α-helix disrupts microbial membranes; modulates host immune response.

What is LL-37 studied for?

LL-37 has been studied in the published literature for: Broad-spectrum antimicrobial; wound healing; biofilm disruption; immune modulation. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is LL-37?

LL-37 is classified as: Cathelicidin antimicrobial peptide; host-defense. Also known as: Cathelicidin; hCAP-18 C-terminus.

Research focus area

All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.

Primary sources

  1. Bandurska K et al. Unique features of human cathelicidin LL-37. Biofactors 2015. PMID 26434733
  2. Xhindoli D et al. The human cathelicidin LL-37 — a pore-forming antibacterial peptide and host-cell modulator. Biochim Biophys Acta 2016. PMID 26556394
  3. Jin X et al. Molecular interaction modes of the host-defense peptide cathelicidin LL-37 and its mutants dictate diverse antimicrobial activities. Nanoscale 2026. PMID 41945358
  4. Tan YL et al. Endogenous cathelicidin protects against Toxoplasma gondii-associated liver damage. Infection and immunity 2026. PMID 41728969
  5. Byun KA et al. Immunomodulatory Effects of Poly-D,L-Lactic Acid on LL-37-Driven Rosacea-like Inflammation via Suppression of mTORC1 Signaling. International journal of molecular sciences 2026. PMID 42511767
  6. Francis F et al. Interfacial activity and membrane interaction of Duttaphrynus melanostictus cathelicidin. Archives of biochemistry and biophysics 2026. PMID 42462895
  7. Fu Q et al. NF-κB/AP-1-mediated expression of the porcine cathelicidin proPMAP-37 suppresses inflammation by neutralizing LPS and inhibiting M1 macrophage polarization. BMC veterinary research 2026. PMID 42458433
  8. Banerjee D et al. Prevalence of Vitamin D Deficiency Among Children With Tuberculosis and Its Relationship With Demographic and Clinical Characteristics. Cureus 2026. PMID 42434643
  9. Khamlaiwong P et al. Functional diversity of cathelicidin peptides in the frog lung: An integrated transcriptomic and functional analysis. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 2026. PMID 42413799
  10. Figgins EL et al. In Vivo Activity of Antimicrobial Peptoid Oligomers against HSV-1 in a Mouse Model of Herpes Labialis. ACS infectious diseases 2026. PMID 42402200
  11. Tsimikas S. LL-37-Apo B100 Complexes: Integrating Lipoprotein Biology and Innate Immunity in Atherogenesis and CAD Risk. Arteriosclerosis, thrombosis, and vascular biology 2026. PMID 42021734
  12. Mu K et al. Lipopolysaccharide-Phospholipid Separation in the Outer Membrane Vesicle Model Promotes Preferential Binding of Antimicrobial Peptides at Lipid Interfaces. Journal of chemical information and modeling 2026. PMID 41952065
  13. Liu Q et al. LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease. Immunity, inflammation and disease 2026. PMID 42095322
  14. Lundberg AT et al. Effect of Fluorescence Photobiomodulation on Canine Progenitor Epidermal Keratinocytes With and Without Staphylococcus pseudintermedius Colonisation. Veterinary dermatology 2026. PMID 42082164
  15. Roy J et al. Comparative molecular characterisation of myeloid cathelicidins reveals subspecies-level diversification in indigenous livestock. Developmental and comparative immunology 2026. PMID 42070472
  16. Xia X et al. Antimicrobial Peptide BSN-37 Enhances Macrophage Immune Activation Through the circBptf-Rbm14-Mediated Regulatory Axis. Probiotics and antimicrobial proteins 2026. PMID 42603258
  17. Botto E et al. Antimicrobial Peptides of the Skin: Roles in Skin Cancer and Clinical Applications. Experimental dermatology 2026. PMID 42576411
  18. Voronko OE et al. Apoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling. International journal of molecular sciences 2026. PMID 42794783
  19. Han W et al. Membrane Disruption and Charge Neutralization Drive Synergy Between LL37-Derived Peptides and Polymyxins Against E. coli. Biomolecules 2026. PMID 42793156
  20. Luo H et al. Cathelicidin LL-37 inhibits angiogenesis and migration in gastric cancer via inhibition of NF-κB/IL-6 signaling. Histology and histopathology 2026. PMID 42745581
  21. Fuertes-Chaves C et al. Exposure to the antimicrobial peptides LL-37 and ATRA-1 induces a lipidome response in Staphylococcus aureus that alters membrane biophysical properties. Biochimica et biophysica acta. Biomembranes 2026. PMID 42303202
  22. Jiang L et al. Chicken cathelicidin-3 protected mice from avian pathogenic Escherichia coli infection mediated by triggering chemokine CCL3 pathway. Veterinary research 2026. PMID 42839251
  23. Shahbaz M et al. Association of Porphyromonas gingivalis peptidylarginine deiminase with CitH3, LL-37, and ACPA in periodontitis and rheumatoid arthritis. Journal of periodontology 2026. PMID 42937026
  24. Wei L et al. Combinatorial therapy of LL-37 and ADSCs accelerates diabetic wound repair by orchestrating NRROS-mediated crosstalk between TGF-β/SMAD and hippo/TEAD1 axes. Cytokine 2026. PMID 42641316

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…